Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several p…
An institutional-grade, numbers-driven thesis on SNY — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates Sanofi SA (SNY) 72/100 with a 12-month base-case forecast of $49.19 — +13.2% versus the current price of $43.46. Sanofi SA trades at $43.46 in the Pharmaceuticals sector, with a market capitalisation of $89.14B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for SNY is $49.19, implying +13.2% versus the current price. The model's 12-month scenario range runs from $44.98 (bear) to $59.04 (bull), with a base case of $49.19.
On the fundamentals, Sanofi SA shows a P/E of 9.5, trailing revenue of $58.56B, revenue growth of +12.1% YoY, a dividend yield of 5.54%. This page also tracks SNY's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
SNY currently carries a TradersQuant composite score of 72/100, which we read as a strong composite signal. The Wall-Street analyst consensus is "hold". Our 12-month price target of $49.19 implies +13.2% from $43.46. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for SNY is $49.19, about +13.2% versus the latest price of $43.46. Consensus is based on 30 analysts.
TradersQuant's 12-month model forecast for SNY is a base case of $49.19, ranging from $44.98 (bear) to $59.04 (bull), an expected return of +13.2%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for SNY over the next 12 months is $49.19 in the base case (bear $44.98, bull $59.04), versus today's price of $43.46. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for SNY — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates SNY's fair value at $59.03, implying +35.8% of expected upside versus the current price.
Yes — Sanofi SA pays a dividend yielding 5.54% (about $2.41 per share annually).
Data and model outputs are for research only and are not financial advice. Figures update continuously.
